MA-MARIANA-ONCO/NOVARTIS
2.5.2024 13:01:28 CEST | Business Wire | Press release
Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, today announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments. The acquisition brings together Mariana Oncology’s innovative radiopharmaceutical pipeline and platform with the proven clinical development and commercialization expertise of Novartis.
Mariana Oncology has developed a robust portfolio of novel peptide based-radiopharmaceuticals targeting a broad spectrum of solid tumor cancers, and has invested in manufacturing capabilities, an extensive isotope supply chain and novel formulations to enhance final product shelf-life. The company’s lead program, MC-339, is a novel radioligand therapy (RLT) designed to target small cell lung cancer.
“Novartis is an established leader in the commercialization of radiopharmaceuticals with a world-class team and global reach. Together, we offer a compelling combination of capabilities,” said Simon Read, Founder and CEO, Mariana Oncology. “In the short time since founding the company, the team at Mariana Oncology has developed a leading radiopharmaceutical discovery platform and an innovative pipeline. Our strategy has centered on overcoming the unique challenges of end-to-end radiopharmaceutical R&D and ultimately, delivery of these drugs to the bedside. Both Mariana and Novartis are committed to transforming cancer care, and together we will be in a better position to do that.”
“This acquisition of Mariana Oncology brings to Novartis phenomenal talent and new capabilities in radioligand therapeutic research that complement our wide-ranging internal research and drug discovery efforts, in addition to our translational and clinical development capabilities,” said Shiva Malek, PhD, Global Head of Oncology for Biomedical Research at Novartis. “This is an ideal pairing, and we are thrilled to continue to do pioneering science together, translating RLT discovery into clinical development to deliver transformative therapies to patients.”
Mariana was founded in 2021 by Atlas Venture, Access Biotechnology and RA Capital Management, and has raised additional funds from other top investors including DeepTrack Capital and Forbion.
The transaction is subject to customary closing conditions.
Centerview Partners LLC served as financial advisor, and Goodwin Procter as legal counsel to Mariana Oncology on the transaction.
About Mariana Oncology
Mariana Oncology is a fully integrated, radiopharmaceutical company pioneering a new standard of care in cancer treatment – targeted peptide-based radioligand therapeutics (RLTs) designed to maximize tumor penetration while minimizing toxicity. Mariana is comprised of some of the world’s leading experts in radiopharmaceutical science and manufacturing who together are pioneering innovations in end-to-end discovery, development and delivery of radioligand therapeutics. The company has developed a portfolio of novel RLTs designed to target a broad range of difficult-to-treat cancers. Mariana’s lead program, MC-339, is an actinium-based radioligand therapeutic being investigated to treat small cell lung cancer.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502315526/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prodalim Strengthens its Functional Platform to Enter the Fast-Growing Nutraceutical Market with the Acquisition of Sylvestre, a Market Leader in Botanical Extracts Based in Brazil12.3.2026 11:45:00 CET | Press release
The acquisition positions Prodalim to deepen its fast-growing functional beverage solutions offering, accelerate its expansion into the US functional ingredients market, and broaden its presence across emerging markets Prodalim, a global leader in juice and specialty ingredients solutions, announced today the acquisition of Sylvestre, a leading Brazilian producer of botanicals and functional extracts addressing the nutraceutical market. Sylvestre’s existing owners and management team will remain with the company and support its integration into Prodalim’s platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312584318/en/ Founded in 1992 in Brazil, Sylvestre is a trusted supplier of high-quality natural ingredients, specializing in botanical extracts, fruit powders, superfruits, teas, and unique functional plant-based solutions sourced from the rich and diverse Brazilian flora. With a portfolio of more than 200 natural
Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 202612.3.2026 11:30:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Stifel 2026 Virtual CNS Forum, from March 17-18, 2026, and will participate in a fireside chat on March 18, 2026, at 10:30am ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our
WHOOP and Samuel Ross MBE Announce First Limited-Edition Collection Drop for PROJECT TERRAIN12.3.2026 11:00:00 CET | Press release
The new WHOOP x SR_A collection includes bespoke, performance-driven WHOOP bands, apparel and outerwear WHOOP, the human performance company, today announces that the first limited-edition collection drop of PROJECT TERRAIN, the multi-year collaboration between WHOOP and Samuel Ross MBE via SR_A, is now available for purchase. The debut collection introduces a technical garment system engineered for movement across environments - redefining the city as a modern training ground for daily performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312513358/en/ WHOOP and Samuel Ross MBE Announce First Limited-Edition Collection Drop for PROJECT TERRAIN PROJECT TERRAIN marks a first for WHOOP, featuring reimagined executions of WHOOP bands, elevated WHOOP Body apparel, and the company’s first entry into technical outerwear. Designed as a unified system, each piece integrates the WHOOP device intentionally and visibly, transf
NAFFCO Group and Verona Shelters Launch Strategic Joint Venture to Scale Civil and Military Shelter Production Globally12.3.2026 10:56:00 CET | Press release
NAFFCO Group has entered into a Joint Venture Agreement with Verona Shelters to form a strategic partnership dedicated to developing and manufacturing advanced civil defense and military shelter solutions in the United Arab Emirates. The partnership significantly expands global production capacity for protective shelter infrastructure at a time when governments and critical industries are strengthening resilience and civil preparedness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312010187/en/ Left: Verona Shelters: Eng. Shaikha Ali Rashed Al Kaabi, (MD UAE) and Mikko Lahtonen, (Executive Director Middle-East); Naffco Group: Eng. Khalid Al-Khatib (CEO); Mr. Ahmed Khalid Al-Khatib, (Group Managing Director); Mr.Ali Khalid Al-Khatib, (Group Managing Director); Ms.Nour Alyazji, (Business Development Director) The collaboration combines NAFFCO’s global leadership in safety engineering and large-scale manufacturing with Ver
Smiths Detection Celebrates Sale of its 2,000th HI-SCAN 6040 CTiX 3D X-ray Scanner12.3.2026 10:00:00 CET | Press release
Major milestone reinforces Smiths Detection’s position as the world’s most trusted provider of advanced screening solutions, deployed at more than 100 airports Smiths Detection, a global leader in threat detection and screening solutions, today announces the sale of its 2,000th HI-SCAN 6040 CTiX, an industry-leading 3D X-ray scanner with high-resolution 3D computed tomography images and intelligent AI-driven automatic detection capabilities. The HI-SCAN 6040 CTiX is deployed across over 100 airports in Europe, Asia-Pacific, the Middle East and the Americas. Operational experience across these regions has demonstrated consistent benefits for airports and passengers alike. Fewer false alarms mean faster, more reliable screening, and as threat profiles change, the technology keeps pace, strengthening security resilience over time. Meanwhile, in eligible locations, passengers no longer need to remove laptops or liquids from their bags, a small change that has a real impact on congestion at
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom